Lin Shen

28.1k citations
398 papers · 21k · 14 hit papers · h-index 58

Impact in

Papers in

Lin Shen

375 papers receiving 20.6k citations

Lin Shen's Hit Papers

Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): final report of a randomised, open-label, phase 3 trial 2025 · 26 citations
260+5+10Years since publication1k2k3k4k5k

Peers

Lin Shen
Comparison fields: 5 of 143
  • Oncology 6.3k
  • Pulmonary and Respiratory Medicine 7k
  • Cancer Research 1.4k
  • Gastroenterology 698
  • Surgery 3k
Replace Nasser Khaled Altorki with:
Nasser Khaled Altorki United States
Yasuhiro Kodera Japan
Kenichi Sugihara Japan
Atsushi Ohtsu Japan
Manisha H. Shah United States
Filip Jankú United States
Yoshiharu Sakai Japan
Bruno Vincenzi Italy
Michael James Overman United States
Stefan Sleijfer Netherlands
Lin Shen relative to Nasser Khaled Altorki United States Nasser Khaled Altorki's profile →
Citations per field
00.5×1.5×2.1×
Nasser Khaled Altorki · 1×
Citations per year

Countries citing papers authored by Lin Shen

Since Specialization
Citations

This map shows the geographic impact of Lin Shen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lin Shen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lin Shen more than expected).

Fields of papers citing papers by Lin Shen

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lin Shen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lin Shen. The network helps show where Lin Shen may publish in the future.

Co-authors

The 25 scholars most cited alongside Lin Shen, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Lin Shen Line = papers co-authored together Lin Shen links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 398 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
Hit paper breakdown →
20105931
2
Granzyme A from cytotoxic lymphocytes cleaves GSDMB to trigger pyroptosis in target cells
Hit paper breakdown →
20201057
3
Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer
Hit paper breakdown →
2020837
4
The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2021
Hit paper breakdown →
2021488
5
Everolimus for Previously Treated Advanced Gastric Cancer: Results of the Randomized, Double-Blind, Phase III GRANITE-1 Study
Hit paper breakdown →
2013406
6
Pertuzumab plus trastuzumab and chemotherapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (JACOB): final analysis of a double-blind, randomised, placebo-controlled phase 3 study
Hit paper breakdown →
2018397
7
Fifteen-Year Effects of Helicobacter pylori, Garlic, and Vitamin Treatments on Gastric Cancer Incidence and Mortality
Hit paper breakdown →
2012391
8 2011342
9 2013338
10 2018327
11
Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): an open-label, superiority and non-inferiority, phase 3 randomised controlled trial
Hit paper breakdown →
2021313
12 2020299
13
Efficacy, Safety, and Correlative Biomarkers of Toripalimab in Previously Treated Recurrent or Metastatic Nasopharyngeal Carcinoma: A Phase II Clinical Trial (POLARIS-02)
Hit paper breakdown →
2021256
14
Tislelizumab Versus Chemotherapy as Second-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma (RATIONALE-302): A Randomized Phase III Study
Hit paper breakdown →
2022226
15
The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2023
Hit paper breakdown →
2023224
16
Effects of Helicobacter pylori treatment and vitamin and garlic supplementation on gastric cancer incidence and mortality: follow-up of a randomized intervention trial
Hit paper breakdown →
2019207
17 2010169
18 2020167
19 2021165
20 2016161

About Lin Shen

Lin Shen is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Gastroenterology, Surgery and Epidemiology, having authored 398 papers that have together received 21k indexed citations. Recurring topics across this work include Gastric Cancer Management and Outcomes (90 papers), Cancer Immunotherapy and Biomarkers (59 papers), Colorectal Cancer Treatments and Studies (51 papers), Esophageal Cancer Research and Treatment (32 papers), Gastrointestinal Tumor Research and Treatment (26 papers), Neuroendocrine Tumor Research Advances (26 papers), HER2/EGFR in Cancer Research (16 papers) and Helicobacter pylori-related gastroenterology studies (9 papers). The work is most often cited by research in Oncology (6.3k citations), Pulmonary and Respiratory Medicine (7k citations), Cancer Research (1.4k citations), Gastroenterology (698 citations) and Surgery (3k citations). Lin Shen has collaborated with scholars based in China, United States and Japan. Frequent co-authors include Yoon‐Koo Kang, Atsushi Ohtsu, Yung‐Jue Bang, Hyun Cheol Chung, Eric Van Cutsem, Akira Sawaki, Taroh Satoh, Andrea Feyereislova, Michaela Lehle and Florian Lordick. Their work appears in journals such as Annals of Oncology, Journal of Clinical Oncology, European Journal of Cancer, Medical Oncology and BMC Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact